4 / 8
Volume 5
Journal of Pharmaceutical Care & Health Systems
Asia Pharma 2018
July 18-20, 2018
Page 13
conference
series
.com
July 18-20, 2018 Melbourne, Australia
15
th
Asia-Pacific Pharma Congress
Discovery of highly potent anti-HCV with new core scaffolds and new conformational aspects
N
S5A is a dimeric protein and an interesting target to inhibit the replication of HCV. Reported here are two series of symmetric
molecules with the scaffolds of 4, 4’-(buta-1,3-diyne- 1,4-diyl) dianiline core- and 3, 3’-(buta-1,3-diyne- 1,4-diyl) dianiline
core, connected to a L/D-proline moiety and capped with the methyl, ethyl, butyl, isobutyl and benzyl carbamate of L/D-valine,
L/D-leucine and L-isoleucine amino acids. The compounds showed inhibitory effect on the replication of HCV genotype 1b
in
vitro
with EC50s in the low picomolar range and SI50s of several orders of magnitude. Also, some of the compounds showed
pan-genotypic activitiy. Higher activities were associated with compounds showing curving of the core scaffolds that leads to
better fit and interaction with the desired target.
Biography
Ashraf H Abadi has completed his PhD from the College of Pharmacy, University of Florida, USA and Cairo University. He is the Head of Pharmaceutical Chemsitry
Department, Faculty of Pharmacy and Biotechnology, German University in Cairo and former Dean of the Faculty. He has published more than 80 papers in reputed
journals; 7 patents and has been serving as an Editorial Board Member and Reviewer of reputed international pharmaceutical sciences journals.
ashraf.abadi@guc.edu.egAshraf H Abadi
German University in Cairo, Egypt
Ashraf H Abadi, J Pharma Care Health Sys 2018, Volume 5
DOI: 10.4172/2376-0419-C1-025